Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.81 |
| ▸ | ADRB1 | P08588 | 19/20 | 0.81 |
| ▸ | ADRA1D | P25100 | 15/20 | 0.81 |
| ▸ | DRD2 | P14416 | 14/20 | 0.81 |
| ▸ | DRD3 | P35462 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801966 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1ADRA1DDRD2DRD3 | |
| SCHEMBL1801968 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1ADRA1DDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL1801313 | 0.89 | ADRB2 (0.98) | ADRB2ADRB1ADRA1DDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL1801315 | 0.89 | ADRB2 (0.98) | ADRB2ADRB1ADRA1DDRD2DRD3 | |
| SCHEMBL1798743 | 0.87 | ADRB2 (0.92) | ADRB2ADRB1ADRA1DDRD2DRD3 | |
| SCHEMBL1798742 | 0.87 | ADRB2 (0.92) | ADRB2ADRB1ADRA1DDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL1798562 | 0.86 | ADRB2 (0.91) | ADRB2ADRB1ADRA1DDRD2DRD3 | |
| SCHEMBL1800695 | 0.86 | ADRB2 (1.00) | ADRB2ADRB1ADRA1DDRD2DRD3 | |
| SCHEMBL1800693 | 0.86 | ADRB2 (1.00) | ADRB2ADRB1ADRA1DDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL1798564 | 0.86 | ADRB2 (0.91) | ADRB2ADRB1ADRA1DDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA UK LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8969350-B2 | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient | ASTRAZENECA AB (SE) | 2015-03-03 | — | — | US | disclosed |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | ASTRAZENECA UK LIMITED (GB) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | NR3C2, GRK4, PTGER2 | ADRB2 34/4885ADRB1 49/4885ADRA1D 146/4885 |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | NR3C2, ARRB1, GRK4 | ADRB2 41/4885ADRB1 46/4885ADRA1D 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.